Anti-Human IL-6 (Sarilumab) - PE
£203.44
Anti-Human IL-6 (Sarilumab) - PE (LT1704-50ug)
Product
| Cat # LT1704-50ug | Size 50 µg |
Price
£203.44
|
Qty
|
Description
IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.
Specifications
| Manufacturer | Leinco Technologies Inc |
|---|---|
| Manufacturer Cat# | LT1704 |
| Product Size | 50 µg |
| Concentration | 0.2 mg/ml |
| Formulation | This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Clone | Hu137 |
| Target | IL-6 |
| Applications | FA, FC, IHC |
| Antigen | IL-6R is ubiquitously expressed. |
| Storage | This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze. |
| Protein | IL-6 |